An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2017
At a glance
- Drugs TAK 935 (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Takeda
- 15 Feb 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 22 Sep 2015 Status changed from not yet recruiting to recruiting,as reported by ClinicalTrials.gov.
- 16 Jul 2015 New trial record